Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma AA, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, van Vollenhoven RF, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken CA, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Autoimmun. 2019 Oct 17:102340. doi: 10.1016/j.jaut.2019.102340. [Epub ahead of print]

2.

IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation.

Zumaquero E, Stone SL, Scharer CD, Jenks SA, Nellore A, Mousseau B, Rosal-Vela A, Botta D, Bradley JE, Wojciechowski W, Ptacek T, Danila MI, Edberg JC, Bridges SL Jr, Kimberly RP, Chatham WW, Schoeb TR, Rosenberg AF, Boss JM, Sanz I, Lund FE.

Elife. 2019 May 15;8. pii: e41641. doi: 10.7554/eLife.41641.

3.

Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial.

Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL Jr, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, Jandali B, Garcia SR, Grossman J, Winthrop KL, Trupin L, Dall'Era M, Meara A, Rizvi T, Chatham WW, Yazdany J.

PLoS Med. 2019 May 8;16(5):e1002800. doi: 10.1371/journal.pmed.1002800. eCollection 2019 May.

4.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.

Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5.

5.

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Rheumatol. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15.

6.

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells.

Hamilton JA, Wu Q, Yang P, Luo B, Liu S, Li J, L Mattheyses A, Sanz I, Chatham WW, Hsu HC, Mountz JD.

J Immunol. 2018 Oct 15;201(8):2203-2208. doi: 10.4049/jimmunol.1800791. Epub 2018 Sep 10.

7.

Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab.

Murthy RK, Jackson J, Chatham WW, Sami N.

J Clin Rheumatol. 2016 Oct;22(7):393-5. doi: 10.1097/RHU.0000000000000447. No abstract available.

PMID:
27660945
8.
9.

A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.

Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, Walter MR, De Benedetti F, Grom AA, Cron RQ.

J Immunol. 2016 Mar 15;196(6):2492-503. doi: 10.4049/jimmunol.1501284. Epub 2016 Feb 15.

10.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM.

Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.

11.

Vasculitis related to viral and other microbial agents.

Teng GG, Chatham WW.

Best Pract Res Clin Rheumatol. 2015 Apr;29(2):226-43. doi: 10.1016/j.berh.2015.05.007. Epub 2015 Jun 11. Review.

PMID:
26362741
12.

Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome?

Cron RQ, Behrens EM, Shakoory B, Ramanan AV, Chatham WW.

J Rheumatol. 2015 Jul;42(7):1078-80. doi: 10.3899/jrheum.150108. No abstract available.

PMID:
26136549
13.

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.

Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B.

Arthritis Rheumatol. 2015 Jul;67(7):1848-57. doi: 10.1002/art.39108.

14.

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T.

Lupus Sci Med. 2014 Oct 1;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014.

15.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

16.

Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations.

Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP.

PLoS Genet. 2013;9(8):e1003678. doi: 10.1371/journal.pgen.1003678. Epub 2013 Aug 8.

17.

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A.

Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669.

18.

Device for carrying blood samples at 37°C for cryoglobulin test.

Nahm MH, Chatham WW, Benjamin WH Jr.

Clin Vaccine Immunol. 2012 Sep;19(9):1555-6. doi: 10.1128/CVI.00295-12. Epub 2012 Jul 18.

19.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

20.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG.

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review. No abstract available.

21.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

22.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

23.

B lymphocytes are resistant to death receptor 5-induced apoptosis.

Crowder RN, Zhao H, Chatham WW, Zhou T, Carter RH.

Clin Immunol. 2011 Apr;139(1):21-31. doi: 10.1016/j.clim.2010.12.006. Epub 2011 Jan 28.

24.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

25.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

26.

Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis.

Xu X, Hsu HC, Chen J, Grizzle WE, Chatham WW, Stockard CR, Wu Q, Yang PA, Holers VM, Mountz JD.

Scand J Immunol. 2009 Sep;70(3):309-16. doi: 10.1111/j.1365-3083.2009.02302.x.

27.

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J.

J Clin Invest. 2009 Jun;119(6):1668-77. doi: 10.1172/JCI38468. Epub 2009 May 26.

28.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology.

Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. No abstract available.

29.

Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?

Chatham WW, Saag KG.

Nat Clin Pract Rheumatol. 2006 May;2(5):240-1. No abstract available.

PMID:
16932692
30.

Ultrasound appearance of knuckle pads.

Lopez-Ben R, Dehghanpisheh K, Chatham WW, Lee DH, Oakes J, Alarcón GS.

Skeletal Radiol. 2006 Nov;35(11):823-7. Epub 2006 May 11.

PMID:
16688449
31.

Improving ambulatory prescribing safety with a handheld decision support system: a randomized controlled trial.

Berner ES, Houston TK, Ray MN, Allison JJ, Heudebert GR, Chatham WW, Kennedy JI Jr, Glandon GL, Norton PA, Crawford MA, Maisiak RS.

J Am Med Inform Assoc. 2006 Mar-Apr;13(2):171-9. Epub 2005 Dec 15.

32.

Immune function in patients with rheumatoid arthritis treated with etanercept.

Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW.

Clin Immunol. 2002 Apr;103(1):13-21.

PMID:
11987981
33.

Treatment of lupus with corticosteroids.

Chatham WW, Kimberly RP.

Lupus. 2001;10(3):140-7. Review.

PMID:
11315342
34.

Renal failure: a risk factor for methotrexate toxicity.

Chatham WW, Morgan SL, Alarcón GS.

Arthritis Rheum. 2000 May;43(5):1185-6. No abstract available.

35.

Update on sarcoidosis.

Jones RE, Chatham WW.

Curr Opin Rheumatol. 1999 Jan;11(1):83-7. Review.

PMID:
9894636
36.
37.

Characterization of PepB, a group B streptococcal oligopeptidase.

Lin B, Averett WF, Novak J, Chatham WW, Hollingshead SK, Coligan JE, Egan ML, Pritchard DG.

Infect Immun. 1996 Aug;64(8):3401-6.

38.

Rheumatoid synovial fibroblast adhesion to human articular cartilage. Enhancement by neutrophil proteases.

McCurdy L, Chatham WW, Blackburn WD Jr.

Arthritis Rheum. 1995 Nov;38(11):1694-700.

PMID:
7488292
39.

Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidase.

Chatham WW, Baggott JE, Loose LD, Blackburn WD Jr.

Biochem Pharmacol. 1995 Sep 7;50(6):811-4.

PMID:
7575642
40.

Progressive joint destruction in a human immunodeficiency virus-infected patient with rheumatoid arthritis.

Müller-Ladner U, Kriegsmann J, Gay RE, Koopman WJ, Gay S, Chatham WW.

Arthritis Rheum. 1995 Sep;38(9):1328-32.

PMID:
7575729
41.

Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenase.

Blackburn WD Jr, Minghetti PP, Schrohenloher RE, Chatham WW.

Clin Immunol Immunopathol. 1995 Sep;76(3 Pt 1):241-7.

PMID:
7554445
42.

Determinants of neutrophil HOCl generation: ligand-dependent responses and the role of surface adhesion.

Chatham WW, Turkiewicz A, Blackburn WD Jr.

J Leukoc Biol. 1994 Nov;56(5):654-60.

PMID:
7964173
43.
44.

Fixation of C3 to IgG attenuates neutrophil HOCl generation and collagenase activation.

Chatham WW, Blackburn WD Jr.

J Immunol. 1993 Jul 15;151(2):949-58.

PMID:
8393040
45.

Degradation of human articular cartilage by neutrophils in synovial fluid.

Chatham WW, Swaim R, Frohsin H Jr, Heck LW, Miller EJ, Blackburn WD Jr.

Arthritis Rheum. 1993 Jan;36(1):51-8.

PMID:
8424836
46.

Additive enhancement of neutrophil collagenase activity by HOCl and cathepsin G.

Chatham WW, Blackburn WD Jr, Heck LW.

Biochem Biophys Res Commun. 1992 Apr 30;184(2):560-7.

PMID:
1315525
47.

Ligand dependent release of activated neutrophil collagenase--a role for surface bound IgG in the degradation of articular collagens.

Chatham WW, Heck LW, Blackburn WD.

Matrix Suppl. 1992;1:207-8. No abstract available.

PMID:
1480027
48.
49.

Lysis of fibrillar collagen by neutrophils in synovial fluid. A role for surface-bound immunoglobulins.

Chatham WW, Heck LW, Blackburn WD Jr.

Arthritis Rheum. 1990 Sep;33(9):1333-9.

PMID:
2169747
50.

Ligand-dependent release of active neutrophil collagenase.

Chatham WW, Heck LW, Blackburn WD Jr.

Arthritis Rheum. 1990 Feb;33(2):228-34.

PMID:
2154997

Supplemental Content

Loading ...
Support Center